Audeo Oncology, Inc. Watch

from S-1/A 74 pages Amendment Deed Between Alchemia Limited and the Registrant.

from S-1/A 22 pages Brisbane Head Office Alchemia Limited (Acn 071 666 334 Abn 43 071 666 334) 3 Hi –Tech Court Brisbane Technology Park Eight Mile Plains Qld 4113 Australia Po Box 4851 Eight Mile Plains Qld 4113 T: 61 7 3340 0200 F: 61 7 3340 0222 Melbourne Office Alchemia Oncology Pty Limited (Acn 058 390 953 Abn 60 058 390 953) Suite 406 Pacific Tower 737 Burwood Road Hawthorn Vic 3122 Australia T: 61 3 8862 6354 F: 61 3 8862 6612 Date Parties Alchemia Oncology Pty Ltd (Employer) Dr Tracey Brown (Executive) Background A. the Employer Carries on the Business of Research and Development, Which Includes Carbohydrate Chemistry and Drug Development Utilising Alchemia Technology. B. the Parties Have Agreed That the Executive Will Be Employed by the Employer on the Terms Set Out in This Agreement. It Is Agreed 1. Definitions in This Agreement, Except to the Extent the Context Otherwise Requires: ‘Agreement’ Means This Executive Employment Agreement;

from S-1/A 20 pages Executive Employment Agreement Alchemia Oncology Pty Ltd Abn: 60 058 390 953 Charles Walker

from S-1/A 21 pages Executive Employment Agreement Alchemia Oncology Pty Ltd Abn: 60 058 390 953 Dr Pete Smith

from S-1/A 14 pages Audeo Oncology, Inc. Indemnification Agreement

from S-1/A 33 pages Audeo Oncology, Inc. 2012 Equity Incentive Plan

from S-1/A 21 pages Audeo Oncology, Inc. 2012 Stock Plan

from S-1/A 20 pages Demerger Deed Poll

from S-1/A 32 pages Transition Services Agreement Ref: Sd/Jaen Alch16282-9082438 7391929/2

from S-1/A 68 pages © Corrs Chambers Westgarth Contents

from S-1/A 95 pages Material contract

from S-1/A 41 pages Technology Licence Agreement Ref: 6708510/13 © Corrs Chambers Westgarth Contents

from S-1/A 49 pages Amendment to Clinical Research Services Agreement

from S-1/A 27 pages Clinical Research Services Agreement

from S-1/A 5 pages 1. Scope of Work Alchemia Oncology Pty Ltd (Hereinafter Referred to as “Alchemia”) Has Requested That Bioclinica, Inc. and Subsidiaries (Hereinafter Referred to as “Bioclinica”) Provide Medical Imaging Core Laboratory Services in Support of Protocol Aco-002. This Addendum Serves to Document the Additional Services Requested for the Study Beyond Those Contained Within the Following: • Agreement #33602 Between Bioclinica and Alchemia, Executed 18 May 2010 • Addendum #33062_1 Between Bioclinica and Alchemia, Executed 29 December 2010 the Addendum Also Serves to Document the Fees for the Additional Services. 1.1. Addendum Assumptions 1.1.1. Assumptions • Revised With Anticipation of Receiving 92% Ct Scans and 3% Mri Scans Due to Possible Contrast Allergy

from S-1/A 8 pages Table 1.1.1

from S-1/A 26 pages General Services Agreement Bioclinica Agreement #33602

from S-1 6 pages Sublease Agreement

from S-1 25 pages 1.1 Definitions in This Document: Aol Means Alchemia Oncology Pty Ltd Acn 058 390 953 of Eight Mile Plains, Brisbane, Queensland 4113. AURX Warrants Means Non-Quoted Options to Subscribe for Fully Paid Shares of Common Stock of AURX on the Terms and Conditions Set Out in Schedule 1. Business Day Means a Day on Which Banks Are Open for Business in Brisbane, Excluding a Saturday, Sunday or Public Holiday

from S-1 25 pages July 13th, 2009 Royalty Agreement Parties Alchemia Oncology Pty Limited Acn 058 390 953 Novozymes Biopharma Dk a/S Contents